NCT02434276View on ClinicalTrials.gov

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

PHASE2UnknownINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

June 30, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

VAX2012Q

Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages

BIOLOGICAL

Fluzone Quadrivalent

Fluzone Quadrivalent (Influenza Vaccine)

Trial Locations (6)

20850

Optimal Research, Rockville

32934

Optimal Research, Melbourne

35802

Optimal Research, Huntsville

46545

Optimal Research, Mishawaka

61614

Optimal Research, Peoria

92108

Optimal Research, San Diego

Sponsors

Collaborators (1)

Accelovance
All Listed Sponsors
collaborator

Accelovance

INDUSTRY

collaborator

Department of Health and Human Services

FED

lead

VaxInnate Corporation

INDUSTRY

NCT02434276 - Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years | Biotech Hunter | Biotech Hunter